Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$144.95 - $152.29 $277 Million - $291 Million
-1,909,218 Reduced 98.99%
19,406 $2.93 Million
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $39.3 Million - $69 Million
-472,660 Reduced 19.68%
1,928,624 $281 Million
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $43.7 Million - $56.8 Million
-397,173 Reduced 14.19%
2,401,284 $285 Million
Q4 2021

Feb 14, 2022

BUY
$99.73 - $148.48 $8.01 Million - $11.9 Million
80,272 Added 2.95%
2,798,457 $386 Million
Q3 2021

Nov 15, 2021

SELL
$98.85 - $138.91 $1.4 Million - $1.97 Million
-14,183 Reduced 0.52%
2,718,185 $378 Million
Q2 2021

Aug 13, 2021

SELL
$65.78 - $105.02 $2.9 Million - $4.63 Million
-44,099 Reduced 1.59%
2,732,368 $265 Million
Q1 2021

May 17, 2021

BUY
$64.07 - $91.75 $14.1 Million - $20.2 Million
219,915 Added 8.6%
2,776,467 $190 Million
Q4 2020

Feb 16, 2021

BUY
$65.07 - $98.24 $1.87 Million - $2.82 Million
28,702 Added 1.14%
2,556,552 $219 Million
Q3 2020

Nov 16, 2020

BUY
$59.04 - $77.95 $1.56 Million - $2.06 Million
26,406 Added 1.06%
2,527,850 $164 Million
Q2 2020

Aug 13, 2020

SELL
$29.01 - $74.23 $1.8 Million - $4.6 Million
-61,999 Reduced 2.42%
2,501,444 $183 Million
Q1 2020

May 15, 2020

BUY
$27.51 - $57.29 $63.6 Million - $133 Million
2,312,881 Added 923.08%
2,563,443 $87.2 Million
Q4 2019

Feb 14, 2020

SELL
$40.86 - $57.65 $11.7 Million - $16.6 Million
-287,235 Reduced 53.41%
250,562 $13.6 Million
Q3 2019

Nov 14, 2019

BUY
$37.38 - $49.47 $9.41 Million - $12.5 Million
251,836 Added 88.07%
537,797 $22.4 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $11.1 Million - $18.7 Million
278,863 Added 3928.75%
285,961 $12.5 Million
Q1 2019

May 14, 2019

BUY
$34.52 - $53.29 $245,022 - $378,252
7,098 New
7,098 $365,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.